Physician profile
Sima Muster
NPI 1508890740
$78,873.44
in general payments reported to CMS, 2019-2025
48 companies · $7,927 in 2025
The $7,927 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $14K · 2021: $10K · 2022: $8,583 · 2023: $15K · 2024: $5,884 · 2025: $7,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $8,715 · Travel and Lodging: $1,509 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,850.00 |
| Food and Beverage | $8,715.25 |
| Travel and Lodging | $1,508.98 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34,522.36 | 2019-2025 | |
| Amarin Pharma, INC. | $18,967.78 | 2019-2023 | |
| Allergan, INC. | $6,197.39 | 2019-2020 | |
| Eisai INC. | $5,283.54 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $2,394.93 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,424.32 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $1,180.72 | 2020-2023 | |
| Lilly USA, LLC | $708.54 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $696.86 | 2019-2022 | |
| Csl Behring | $691.68 | 2022-2025 | Haegarda, Kcentra, Andembry |
| E.R. Squibb & Sons, L.L.C. | $651.00 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $633.64 | 2019-2024 | Myrbetriq, Veozah |
| Amgen INC. | $553.62 | 2019-2025 | Otezla, Repatha, Evenity |
| Nestle Healthcare Nutrition INC. | $552.74 | 2020-2023 | |
| Pfizer INC. | $438.28 | 2019-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Muster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.